Zobrazeno 1 - 10
of 206
pro vyhledávání: '"Peter C, Huijgens"'
Autor:
Manon S. Boddaert, Joep Douma, Anne-Floor Q. Dijxhoorn, René A. C. L. Héman, Carin C. D. van der Rijt, Saskia S. C. M. Teunissen, Peter C. Huijgens, Kris C. P. Vissers
Publikováno v:
PLoS ONE, Vol 17, Iss 3 (2022)
In a predominantly biomedical healthcare model focused on cure, providing optimal, person-centred palliative care is challenging. The general public, patients, and healthcare professionals are often unaware of palliative care’s benefits. Poor inter
Externí odkaz:
https://doaj.org/article/54fcc0328f2e47ac9fd3b15fce101ea9
Autor:
Marissa C van Maaren, Robert F Kneepkens, Joke Verbaan, Peter C Huijgens, Valery E P P Lemmens, Rob H A Verhoeven, Sabine Siesling
Publikováno v:
PLoS ONE, Vol 14, Iss 1, p e0210887 (2019)
OBJECTIVE:Many cancer survivors are facing difficulties in getting a life insurance; raised premiums and declinatures are common. We generated a prediction model estimating the conditional extra mortality risk of breast cancer patients in the Netherl
Externí odkaz:
https://doaj.org/article/9ee22b4ccbaa47eab9e4a51f87173d53
Publikováno v:
TSG - Tijdschrift voor gezondheidswetenschappen. 99:1-8
SamenvattingDe COVID-19-crisis en de intelligente lockdown hebben ertoe geleid dat het Nederlandse zorgsysteem maandenlang voor niet-COVID-patiënten op slot kwam te zitten. Patiënten durfden of konden niet naar hun huisarts, huisartsen waren terugh
Autor:
Djamila E. Issa, Saskia A.M. van de Schans, Martine E.D. Chamuleau, Henrike E. Karim-Kos, Marielle Wondergem, Peter C. Huijgens, Jan Willem W. Coebergh, Sonja Zweegman, Otto Visser
Publikováno v:
Haematologica, Vol 100, Iss 4 (2015)
Only a small number of patients with aggressive B-cell lymphoma take part in clinical trials, and elderly patients in particular are under-represented. Therefore, we studied data of the population-based nationwide Netherlands Cancer Registry to deter
Externí odkaz:
https://doaj.org/article/93492b86e83f4fb7b651abe978f4a1f0
Autor:
Jaap J. Zwaginga, Bronno van der Holt, Peter A. te Boekhorst, Bart J. Biemond, Mark-David Levin, René van der Griend, Anneke Brand, Sonja Zweegman, Hans F.M. Pruijt, Vera M.J. Novotny, Art Vreugdenhil, Marco R. de Groot, Okke de Weerdt, Elisabeth C.M. van Pampus, Tanja M. van Maanen-Lamme, Shulamiet Wittebol, Martin R. Schipperus, Matthijs H. Silbermann, Peter C. Huijgens, Marleen Luten, Rene Hollestein, Jan A.C. Brakenhoff, Jolanda G. Schrama, Fransje A.A. Valster, Gerjo A. Velders, Harry R. Koene
Publikováno v:
Haematologica, Vol 100, Iss 3 (2015)
Externí odkaz:
https://doaj.org/article/aa9c02bce86b43a7ad184444996b6a14
Autor:
Hedwig M. Blommestein, Peter C. Huijgens, Martine E D Chamuleau, Marielle J. Wondergem, Pieternella J. Lugtenburg, Sonja Zweegman, Otto Visser, Avinash G Dinmohamed, Djamila E. Issa
Publikováno v:
Leukemia and Lymphoma, 62(3), 549-559. Informa Healthcare
Issa, D E, Dinmohamed, A G, Wondergem, M J, Blommestein, H M, Huijgens, P C, Lugtenburg, P J, Visser, O, Zweegman, S & Chamuleau, M E D 2021, ' A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands ', Leukemia and Lymphoma, vol. 62, no. 3, pp. 549-559 . https://doi.org/10.1080/10428194.2020.1842394
Leukemia & Lymphoma, 62(3), 549-559. Informa Healthcare
Issa, D E, Dinmohamed, A G, Wondergem, M J, Blommestein, H M, Huijgens, P C, Lugtenburg, P J, Visser, O, Zweegman, S & Chamuleau, M E D 2021, ' A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands ', Leukemia and Lymphoma, vol. 62, no. 3, pp. 549-559 . https://doi.org/10.1080/10428194.2020.1842394
Leukemia & Lymphoma, 62(3), 549-559. Informa Healthcare
Randomized controlled trials have studied different dose-intensity and dose-interval regimens of R-CHOP for patients with diffuse large B-cell lymphoma (DLBCL). This study was undertaken to confirm these results in a population-based setting, with sp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd80c0df9c566fd9d22f89453d0d3613
https://research.vumc.nl/en/publications/6d192bf1-7d92-4686-8e76-7bc22396386a
https://research.vumc.nl/en/publications/6d192bf1-7d92-4686-8e76-7bc22396386a
Autor:
Gerrit Glas, Dirk J Kruijthoff, Cornelis van der Kooi, Peter C. Huijgens, Elena Bendien, Tineke A. Abma
Publikováno v:
Explore. Elsevier Inc.
Kruijthoff, D J, Bendien, E, van der Kooi, C, Glas, G, Abma, T A & Huijgens, P C 2021, ' Three cases of hearing impairment with surprising subjective improvements after prayer. What can we say when analyzing them? ', Explore . https://doi.org/10.1016/j.explore.2021.05.001
Kruijthoff, D J, Bendien, E, van der Kooi, C, Glas, G, Abma, T A & Huijgens, P C 2022, ' Three cases of hearing impairment with surprising subjective improvements after prayer. What can we say when analyzing them? ', Explore, vol. 18, no. 4, pp. 475-482 . https://doi.org/10.1016/j.explore.2021.05.001
Explore, 18(4), 475-482. Elsevier Inc.
Kruijthoff, D J, Bendien, E, van der Kooi, C, Glas, G, Abma, T A & Huijgens, P C 2021, ' Three cases of hearing impairment with surprising subjective improvements after prayer. What can we say when analyzing them? ', Explore . https://doi.org/10.1016/j.explore.2021.05.001
Kruijthoff, D J, Bendien, E, van der Kooi, C, Glas, G, Abma, T A & Huijgens, P C 2022, ' Three cases of hearing impairment with surprising subjective improvements after prayer. What can we say when analyzing them? ', Explore, vol. 18, no. 4, pp. 475-482 . https://doi.org/10.1016/j.explore.2021.05.001
Explore, 18(4), 475-482. Elsevier Inc.
Aim to enhance the understanding of documented mismatches between ‘subjective’ experiences and ‘objective’ data in three cases of self-reported instantaneous healing of hearing impairment upon prayer. Method description of three cases taken o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1de0fcbf6b5639b7d70ea2cf683ae735
https://research.vumc.nl/en/publications/dc1867a4-03f2-47fe-a3ba-730821eea624
https://research.vumc.nl/en/publications/dc1867a4-03f2-47fe-a3ba-730821eea624
Autor:
Sonja Zweegman, Nicole M. A. Blijlevens, Pieter Sonneveld, Carin A. Uyl-de Groot, Hedwig M. Blommestein, Peter C. Huijgens, Margreet G. Franken, Chrissy H. Y. Van Beurden-Tan
Publikováno v:
JAMA Network Open, 4, 3
Blommestein, H M, Franken, M G, Van Beurden-Tan, C H Y, Blijlevens, N M A, Huijgens, P C, Sonneveld, P, Uyl-De Groot, C A & Zweegman, S 2021, ' Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients with Multiple Myeloma ', JAMA network open, vol. 4, no. 3, e213497 . https://doi.org/10.1001/jamanetworkopen.2021.3497
JAMA network open, 4(3):e213497. American Medical Association
JAMA Network Open, 4
JAMA Network Open
Blommestein, H M, Franken, M G, Van Beurden-Tan, C H Y, Blijlevens, N M A, Huijgens, P C, Sonneveld, P, Uyl-De Groot, C A & Zweegman, S 2021, ' Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients with Multiple Myeloma ', JAMA network open, vol. 4, no. 3, e213497 . https://doi.org/10.1001/jamanetworkopen.2021.3497
JAMA network open, 4(3):e213497. American Medical Association
JAMA Network Open, 4
JAMA Network Open
Key Points Question What is the optimal sequence of treatments for patients with multiple myeloma from the perspective of the patient, physician, and society? Findings This economic evaluation found that sequences starting with daratumumab-bortezomib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fde32050887d161fa34068c8a2f1e15
https://repository.ubn.ru.nl/handle/2066/245028
https://repository.ubn.ru.nl/handle/2066/245028
Publikováno v:
Tsg
Samenvatting De COVID-19-crisis en de intelligente lockdown hebben ertoe geleid dat het Nederlandse zorgsysteem maandenlang voor niet-COVID-patiënten op slot kwam te zitten. Patiënten durfden of konden niet naar hun huisarts, huisartsen waren terug
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 5, Iss 1, Pp e2013018-e2013018 (2013)
Treatment outcome in elderly Acute Myeloid Leukemia (AML) is still very disappointing. Although complete remission rate is around 50-60% the 2 years survival is only in the magnitude of 10-20%. This is mainly due to an overrepresentation of adverse p
Externí odkaz:
https://doaj.org/article/7b5c911d4b93416ebb0dddcccadede97